Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
29 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
CellAct Pharma GmbH - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'CellAct Pharma GmbH - Product Pipeline Review - 2014', provides an overview of the CellAct Pharma GmbH's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of CellAct Pharma GmbH's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of CellAct Pharma GmbH including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of CellAct Pharma GmbH's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the CellAct Pharma GmbH's pipeline products Reasons to buy - Evaluate CellAct Pharma GmbH's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of CellAct Pharma GmbH in its therapy areas of focus - Identify new drug targets and therapeutic classes in the CellAct Pharma GmbH's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of CellAct Pharma GmbH and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of CellAct Pharma GmbH - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of CellAct Pharma GmbH and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 CellAct Pharma GmbH Snapshot 5 CellAct Pharma GmbH Overview 5 Key Information 5 Key Facts 5 CellAct Pharma GmbH - Research and Development Overview 6 Key Therapeutic Areas 6 CellAct Pharma GmbH - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 CellAct Pharma GmbH - Pipeline Products Glance 11 CellAct Pharma GmbH - Clinical Stage Pipeline Products 11 Phase II Products/Combination Treatment Modalities 11 CellAct Pharma GmbH - Early Stage Pipeline Products 12 Preclinical Products/Combination Treatment Modalities 12 CellAct Pharma GmbH - Drug Profiles 13 CAP-7.1 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 CAP-1.2 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 CAP-2.1 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 CAP-2.2 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 CAP-3.1 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 CAP-3.2 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 CAP1.1 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 CellAct Pharma GmbH - Pipeline Analysis 21 CellAct Pharma GmbH - Pipeline Products by Target 21 CellAct Pharma GmbH - Pipeline Products by Route of Administration 22 CellAct Pharma GmbH - Pipeline Products by Molecule Type 23 CellAct Pharma GmbH - Pipeline Products by Mechanism of Action 24 CellAct Pharma GmbH - Recent Pipeline Updates 25 CellAct Pharma GmbH - Dormant Projects 26 CellAct Pharma GmbH - Locations And Subsidiaries 27 Head Office 27 Appendix 28 Methodology 28 Coverage 28 Secondary Research 28 Primary Research 28 Expert Panel Validation 28 Contact Us 29 Disclaimer 29
List of Tables CellAct Pharma GmbH, Key Information 5 CellAct Pharma GmbH, Key Facts 5 CellAct Pharma GmbH - Pipeline by Indication, 2014 8 CellAct Pharma GmbH - Pipeline by Stage of Development, 2014 9 CellAct Pharma GmbH - Monotherapy Products in Pipeline, 2014 10 CellAct Pharma GmbH - Phase II, 2014 11 CellAct Pharma GmbH - Preclinical, 2014 12 CellAct Pharma GmbH - Pipeline by Target, 2014 21 CellAct Pharma GmbH - Pipeline by Route of Administration, 2014 22 CellAct Pharma GmbH - Pipeline by Molecule Type, 2014 23 CellAct Pharma GmbH - Pipeline Products by Mechanism of Action, 2014 24 CellAct Pharma GmbH - Recent Pipeline Updates, 2014 25 CellAct Pharma GmbH - Dormant Developmental Projects,2014 26
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.